Blog

atai Life Sciences to Participate in Upcoming May Investor Conference

May 4 • 2 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference. Details of the company’s presentation is as follows: Aegis Virtual ConferenceFormat: Corporate PresentationDate and Time: Wednesday, May 3rd, 11:30 a.m. ETLocation: Virtual A live webcast of the presentation will be…

Oregon’s Psilocybin Marketplace Could Be Facing a Serious Bottleneck

May 2 • 3 min read

It’s been a few months since the Oregon Health Authority (OHA) finally announced its regulations around legal medicinal psilocybin—the hallucinogenic compound found in magic mushrooms. And since then, applications have been pouring in for professional licenses to offer psilocybin services. But there’s a serious problem… Based on the current applications streaming in, Oregon could see…

Blackhawk and Mindbio Therapeutics Corp. (formerly, 1286409 B.C. LTD.) Announce Completion of Plan of Arrangement

May 2 • 3 min read

Blackhawk Growth Corp. (CSE: BLR / FSE: 0JJ) and MindBio Therapeutics Corp. (formerly, 1286409 B.C. Ltd.) are pleased to announce the completion of the previously announced plan of arrangement (the “Arrangement”) pursuant to which Blackhawk completed a spin-out of the common shares of MindBio . Arrangement As a result of the Arrangement, Blackhawk re-designated its issued and unissued…

Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

May 2 • 7 min read

Incannex Healthcare Limited (Nasdaq: IXHL / ASX: IHL), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has received final results from the Phase 1 clinical trial undertaken to assess pharmacokinetics and safety of the anti-inflammatory drug IHL-675A. IHL-675A is…

Update on Release of the 2022 Year End Financials and Board Of Directors

May 2 • 3 min read

Irwin Naturals Inc. (CSE: IWIN / OTC: IWINF / FRA: 97X) announces that the British Columbia Securities Commission has issued a failure-to-file-cease trade order (“CTO”) pursuant to National Policy 11-207 – Failure to File Cease Trade Orders and Revocations in Multiple Jurisdictions in respect of the securities of the Company as a result of the Company not having…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538